Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 2,761

Document Document Title
WO/2000/059474A1
Novel lipid compounds are provided that may be termed 'pro-cationic' in that they are neutral or negatively charged until they are either brought into contact with cellular membranes or are internalized by cells. The lipids have a hydrop...  
WO/2000/059921A1
An end product mixture substantially comprising saturated phytosterols is prepared from a raw material mixture of phytosterols derived from tall oil. At least a substantial portion of the raw material mixture consists of unsaturated phyt...  
WO/2000/058338A1
Disclosed are compositions and methods for promoting plant growth. The compounds are cyclopropyl-, cyclobutyl- and cyclopentyl-substituted brassinosteroids having high growth promoting ability. They may be used alone or in combination wi...  
WO/2000/056758A1
The invention relates to a method for representing compounds of the general formula (1). The invention further relates to the hitherto unknown compounds of general formulas (5, 6 and 7) in the form of intermediate products and to the use...  
WO/2000/056759A1
Steroid derivatives useful as the intermediate for preparing vitamin D derivatives such as 1$g(a), 25-dihydroxyvitamin D¿3? and 2$g(b)-(3-hydroxypropoxy)-1$g(a), 25-dihydroxyvitamin D¿3?, i.e., halides of general formula (II) (wherein ...  
WO/2000/056757A1
The invention provides compositions comprising formula 1 steroids, e.g., 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. Th...  
WO/2000/054780A2
A unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90 % by weight of the corticosteroid, 2 to 8 hours after administra...  
WO/2000/054756A2
Compounds and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject are described. Neurological or cognitive conditions are treated by administering to a subject an effect...  
WO/2000/053618A1
The invention relates to 22R-hydroxycholesta-8,14-diene derivatives having general formula (I) wherein R¿1? is OR, OSO¿3?H or =NOR; with R being H, (C¿1-6?)alkyl or (C¿1-6?)acyl; each of R¿2? and R¿3? is independently hydrogen or (...  
WO/2000/052142A2
The present invention relates to the use of a new principle for improving the viability and pregnancy potential of oocytes and pre-embryos obtained in connection with in vitro fertilisation and pre-embryo transfer treatment. More specifi...  
WO/2000/051618A1
The invention relates to (androst-5-en-17$g(b)-yl)alkyl sulfoxides and sulfones having general formula (I), wherein R¿1? is (H, OR), (H, OSO¿3?H) or NOR; with R being H, (C¿1-6?)alkyl or (C¿1-6?)acyl; each of R¿2? and R¿3? is indep...  
WO/2000/048608A1
Efficacious preparations for intravenous administration containing ginsenoside Rb¿1? or its salt which are useful as vascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors. These preparations a...  
WO/2000/047649A1
The invention relates to novel double metal cyanide (DMC) catalyts for producing polyether polyols by polyaddition of alkylene oxides to starter compounds with active hydrogen atoms. The catalyst contains a) double metal cyanide compound...  
WO/2000/047570A1
The invention relates to a method for producing phytosterols by interesterifiying residues from the production of methyl esters with methanol, using an alkaline catalyst, neutralising the catalyst and separating the unreacted alcohol. Th...  
WO/2000/047604A1
The present invention relates to pharmaceutically active unsaturated cholestane derivatives, to pharmaceutical compositions comprising them as active substances and to the use of these novel compounds for the preparation of medicaments. ...  
WO/2000/041699A1
The present invention relates to the use of estrogens and delta-gonadien-21-0l-3,20-diones in the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or f...  
WO/2000/035938A1
The invention relates to 22S-hydroxycholesta-8, 14-diene derivatives having general formula (I) wherein R¿1? is OR, OSO¿3?H or = NOR; with R being H, (C¿1-6?) alkyl or (C¿1-6?) acyl; each of R¿2? and R¿3? is independently hydrogen ...  
WO/2000/034305A1
Isolation of the sterol component of a sterol-rich fraction of saponified tall oil pitch is disclosed. Sterol isolation is accomplished by deriving from the tall oil pitch a sterolrich fraction in a hydrocarbon (preferably heptane) phase...  
WO/2000/034307A1
The invention relates to sterol phosphates of formula (I) in which R?1¿, R¿2? and R?4¿, independent of one another, represent H and/or methyl and R?3¿ represents linear and/or branched alkyl radicals and/or alkenyl radicals with 1 to...  
WO/2000/027867A1
Sterols from the solvent-extracted or distilled neutrals of saponified tall oil pitch are disclosed to be isolated and purified by a process of a liquid-liquid extraction where the hydrocarbon extraction stream is washed with an aqueous ...  
WO/2000/024761A1
The invention relates to substituted phenyl alkenoyl guanidines, the pharmaceutically acceptable salts thereof, and physiolgically functional derivatives. Compounds of formula (I) are disclosed, wherein the radicals have the meanings thu...  
WO/2000/023141A1
This invention is an electrical stimulation of the vomeronasal organ (VNO) in humans to affect hypothalamic activity to influence autonomic function, to regulate hormone levels, particularly for contraception, and treatment of diseases i...  
WO/2000/023138A1
Occlusion of the vomeronasal organ (VNO) in humans is a method for affecting hypothalamic activity, and may be used for regulating hormone levels, influencing autonomic function, and decreasing the risk of spontaneous miscarriage. VNO (1...  
WO/2000/020437A1
The invention relates to substituted propanolamine derivatives and their pharmaceutically acceptable salts and physiologically functional derivatives. The invention relates to compounds of formula (I), wherein the radicals have the defin...  
WO/2000/015652A1
A method is set forth for separating a sterol or sterol ester from crude tall oil comprising fractionating the crude tall oil into a residue fraction and a volatile fraction, wherein the temperature of the residue fraction does not excee...  
WO/2000/012533A1
Isolation of the sterol component of the neutrals fraction of saponified tall oil pitch is disclosed. Sterol isolation is accomplished by a liquid-liquid extraction from the tall oil pitch-derived neutrals, resulting in a hydrocarbon (pr...  
WO/2000/009535A1
Isolation of the sterol component of the neutrals fraction of saponified tall oil pitch is disclosed. To the extracted neutrals, in a hydrocarbon (preferably heptane) phase, are added small amounts of water and an alcohol solvent, prefer...  
WO/2000/004038A1
Sterols from the neutrals fraction of tall oil pitch are disclosed to be isolated and purified by a process of a liquid-liquid extraction where the hydrocarbon extraction stream is washed with an aqueous methanol solution to remove metha...  
WO/2000/004039A1
Sterols from the neutrals fraction of tall oil pitch are disclosed to be isolated and purified by a process of a liquid-liquid extraction where the hydrocarbon extraction stream is washed with an aqueous methanol solution to remove metha...  
WO/1999/067273A1
Certain novel sterol derivatives having no hydroxy group in the 3 position can be used to regulate the meiosis in oocytes and in male germ cells.  
WO/1999/065462A2
Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride (Cl?-¿) channel regulated by phosphorylation and intracellular nucleotides. CFTR is the major Cl?-¿ transport pathway in airway epithelial cells. The abnormal tra...  
WO/1999/063841A1
A composition suitable for incorporation into foods, beverages, pharmaceuticals, nutraceuticals and the like comprises one or more phytosterols, phytostanols or mixtures of both, treated to enhance the solubility and dispersability thereof.  
WO/1999/058549A1
Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.  
WO/1999/056558A1
This invention relates to phytosterols and phytostanols, in particular to fatty acid esters of phytosterols and phytostanols with a specified fatty acid composition. The invention further relates to methods for preparation of the phytost...  
WO/1999/052863A1
Vitamin D derivatives represented by general formula (I), intermediate compounds in the synthesis thereof, and medicinal compositions containing these vitamin D derivatives as the active ingredient wherein A represents linear or branched...  
WO/1999/052930A1
The invention relates to a new method comprising different ways of producing compounds of formula (1). The invention further relates to the hitherto unknown compounds of formulas (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13),...  
WO/1999/052932A1
The present invention relates to bile acid or bile salt fatty acid conjugates (hereinafter called 'BAFAC'), to their use in dissolving cholesterol gallstones in bile, preventing their occurrence or recurrence, to their use in reducing or...  
WO/1999/048907A1
The invention relates to a method for producing stanols. Stanols are hydrogenated in the presence of palladium catalysts in an organic solution. Alcohol, paraffin carbohydrates and mixtures of alcohol and carbohydrates can be used as sol...  
WO/1999/047485A1
A procedure for oxidizing organic compounds having allylic hydrogen atom(s) involving the steps of reactively contacting the organic compound with a combination of an N-hydroxy dicarboxylic acid imide and a chromium-containing oxidant. T...  
WO/1999/045931A1
The use of epiallopregnanolone (3$g(b)-hydroxy-5$g(a)-pregnan-20-one) for the treatment of $i(inter alia) steroid induced mood disorders and CNS disorders is disclosed. Further, the use of epiallopregnanolone for the manufacture of pharm...  
WO/1999/046279A2
Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17$g(b)-hydroxy...  
WO/1999/046280A1
The invention concerns compounds of formula (I) wherein: R1 represents a C1-C31 hydrocarbon radical, in particular an alkyl radical, linear or branched, saturated or unsaturated; OR2 represents a cholesteryl radical; said compounds being...  
WO/1999/044442A1
The invention concerns a stable homogeneous emulsifier-free suspension of at least one hydrophobic substance and/or a substance whereof the melting point is higher than about 130 °C, and a thickening agent, in an aqueous medium. Said su...  
WO/1999/043698A1
A separation method by which a compound having an antitumor effect contained in vegetative wasp can be obtained in a pure state. Also, the chemical structure of this antitumor compound is clarified.  
WO/1999/042471A1
A method of preparing phytosterols from tall oil pitch containing steryl esters comprises the steps of converting the steryl esters to free phytosterols while in the pitch to produce a modified pitch containing the free phytosterols; rem...  
WO/1999/041272A1
A method of isolating a purified tall oil sterol from neutral tall oil components, characterized by: (a) contacting the neutral tall oil components with at least one solvent selected from the group consisting of methanol, hydrous methano...  
WO/1999/037701A1
Cholesteric polymer P1 obtainable by a ring-opening metathesis polymerization ('ROMP') of (a) from 10 to 50 mol-% of a monomer with the formula (I): Z(B¿1?)¿y?; (b) from 90 to 50 mol -% of (b1) from 0 to 100 mol -%, related to the sum ...  
WO/1999/032127A1
Compositions of angiostatic agents for treating GLC1A glaucoma and methods for their use are disclosed.  
WO/1999/032506A1
The invention relates to 17$g(b)-aryl(arylmethyl)oxy(thio)alkyl-androstane derivatives having general formula (I), wherein R¿1? is (H,OR), (H,OSO¿3?H) or NOR; with R being H, (C¿1-6?)alkyl or (C¿1-6?)acyl; each of R¿2? and R¿3? is ...  
WO/1999/019342A1
The present invention relates to bile acid metal salts of therapeutical interest, as well as to pharmaceutical and veterinary compositions containing said salts.  

Matches 601 - 650 out of 2,761